

Table 7 (Web Supplement). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Male							
All Sites	444.1	565.6	650.2	0.79	(0.78 - 0.79) ^e	0.68	(0.68 - 0.69) ^e
Oral Cavity and Pharynx	11.4	16.4	18.3	0.70	(0.68 - 0.72) ^e	0.62	(0.60 - 0.65) ^e
Lip	0.6	1.7	0.1	0.37	(0.32 - 0.43) ^e	4.32	(3.15 - 5.94) ^e
Tongue	2.6	4.2	3.9	0.61	(0.57 - 0.65) ^e	0.66	(0.60 - 0.71) ^e
Salivary Gland	1.1	1.7	1.1	0.63	(0.56 - 0.71) ^e	0.97	(0.84 - 1.13)
Floor of Mouth	0.8	1.1	1.6	0.68	(0.60 - 0.78) ^e	0.47	(0.41 - 0.55) ^e
Gum and Other Mouth	1.6	2.0	2.5	0.79	(0.72 - 0.87) ^e	0.61	(0.55 - 0.68) ^e
Nasopharynx	0.7	0.6	1.2	1.09	(0.95 - 1.24)	0.57	(0.49 - 0.66) ^e
Tonsil	1.8	2.5	2.8	0.70	(0.65 - 0.76) ^e	0.64	(0.58 - 0.70) ^e
Oropharynx	0.6	0.6	1.3	0.90	(0.77 - 1.05)	0.43	(0.36 - 0.51) ^e
Hypopharynx	1.3	1.3	2.7	1.02	(0.92 - 1.14)	0.49	(0.44 - 0.55) ^e
Other Oral Cavity and Pharynx	0.5	0.5	1.0	0.98	(0.83 - 1.16)	0.50	(0.42 - 0.61) ^e
Digestive System	107.4	108.4	136.8	0.99	(0.98 - 1.00)	0.79	(0.77 - 0.80) ^e
Esophagus	5.7	8.7	12.3	0.66	(0.63 - 0.70) ^e	0.47	(0.44 - 0.49) ^e
Stomach	16.1	9.2	17.6	1.75	(1.70 - 1.81) ^e	0.91	(0.88 - 0.95) ^e
Small Intestine	1.6	2.0	3.3	0.77	(0.70 - 0.84) ^e	0.47	(0.42 - 0.53) ^e
Colon and Rectum	52.4	64.6	71.3	0.81	(0.80 - 0.82) ^e	0.73	(0.72 - 0.75) ^e
Colon excluding Rectum	35.8	45.4	54.6	0.79	(0.77 - 0.80) ^e	0.66	(0.64 - 0.67) ^e
Cecum	6.4	9.3	10.8	0.70	(0.66 - 0.73) ^e	0.60	(0.56 - 0.63) ^e
Appendix	0.4	0.6	0.5	0.60	(0.50 - 0.73) ^e	0.65	(0.52 - 0.82) ^e
Ascending Colon	5.9	7.5	9.0	0.79	(0.75 - 0.83) ^e	0.66	(0.62 - 0.70) ^e
Hepatic Flexure	2.1	2.5	2.7	0.83	(0.76 - 0.91) ^e	0.75	(0.68 - 0.84) ^e
Transverse Colon	2.6	3.8	4.6	0.68	(0.63 - 0.73) ^e	0.56	(0.51 - 0.62) ^e
Splenic Flexure	1.1	1.6	2.6	0.70	(0.63 - 0.79) ^e	0.44	(0.39 - 0.50) ^e
Descending Colon	2.3	2.7	4.3	0.85	(0.79 - 0.92) ^e	0.54	(0.49 - 0.59) ^e
Sigmoid Colon	11.8	14.0	13.9	0.84	(0.81 - 0.87) ^e	0.85	(0.81 - 0.89) ^e
Large Intestine, NOS	3.2	3.5	6.1	0.92	(0.86 - 0.99) ^e	0.53	(0.49 - 0.57) ^e
Rectum and Rectosigmoid Junction	16.5	19.2	16.7	0.86	(0.84 - 0.89) ^e	0.99	(0.95 - 1.03)
Rectosigmoid Junction	5.0	5.7	4.6	0.88	(0.83 - 0.92) ^e	1.08	(1.01 - 1.15) ^e
Rectum	11.6	13.5	12.1	0.86	(0.83 - 0.89) ^e	0.95	(0.91 - 1.00) ^e
Anus, Anal Canal and Anorectum	1.0	1.2	1.5	0.82	(0.74 - 0.92) ^e	0.67	(0.59 - 0.77) ^e
Liver and Intrahepatic Bile Duct	14.8	6.5	11.2	2.28	(2.21 - 2.35) ^e	1.32	(1.27 - 1.38) ^e
Liver	13.9	5.8	10.5	2.40	(2.33 - 2.48) ^e	1.32	(1.26 - 1.37) ^e
Intrahepatic Bile Duct	1.0	0.7	0.7	1.30	(1.14 - 1.48) ^e	1.39	(1.16 - 1.66) ^e
Hepatocellular	11.6	4.5	8.5	2.60	(2.51 - 2.70) ^e	1.36	(1.30 - 1.42) ^e
Gallbladder	1.4	0.7	0.9	1.88	(1.68 - 2.10) ^e	1.51	(1.30 - 1.76) ^e
Other Biliary	2.4	1.9	1.5	1.29	(1.19 - 1.40) ^e	1.62	(1.44 - 1.82) ^e
Pancreas	11.1	12.7	16.1	0.87	(0.84 - 0.91) ^e	0.69	(0.66 - 0.72) ^e
Retroperitoneum	0.4	0.4	0.3	0.88	(0.74 - 1.06)	1.05	(0.82 - 1.34)
Peritoneum, Omentum and Mesentery	0.1	0.1	0.1	1.22	(0.84 - 1.76)	1.28	(0.78 - 2.08)
Other Digestive Organs	0.5	0.4	0.5	1.20	(1.00 - 1.44)	0.96	(0.76 - 1.22)
Respiratory System	60.6	100.3	126.2	0.60	(0.60 - 0.61) ^e	0.48	(0.47 - 0.49) ^e
Nose, Nasal Cavity and Middle Ear	0.8	0.9	0.9	0.94	(0.83 - 1.07)	0.91	(0.78 - 1.07)
Larynx	6.8	7.4	12.1	0.91	(0.87 - 0.95) ^e	0.56	(0.53 - 0.59) ^e

Table 7 (Web Supplement). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Lung and Bronchus	52.7	91.7	112.8	0.57	(0.57 - 0.58) ^e	0.47	(0.46 - 0.48) ^e
Pleura	0.0	0.1	0.0	0.56	(0.26 - 1.15)	0.78	(0.30 - 1.99)
Trachea, Mediastinum and Other Respiratory Organs	0.3	0.3	0.3	1.02	(0.85 - 1.23)	1.10	(0.85 - 1.44)
Bones and Joints	1.1	1.1	0.9	0.96	(0.88 - 1.06)	1.20	(1.06 - 1.37) ^e
Soft Tissue including Heart	3.0	3.5	3.4	0.85	(0.80 - 0.90) ^e	0.88	(0.81 - 0.95) ^e
Skin excluding Basal and Squamous	5.6	26.4	2.1	0.21	(0.20 - 0.22) ^e	2.67	(2.46 - 2.90) ^e
Melanoma of the Skin	4.6	24.4	1.1	0.19	(0.18 - 0.20) ^e	4.19	(3.75 - 4.69) ^e
Other Non-Epithelial Skin	0.9	2.0	1.0	0.47	(0.41 - 0.52) ^e	0.96	(0.82 - 1.11)
Breast	1.0	1.5	2.1	0.66	(0.58 - 0.74) ^e	0.46	(0.40 - 0.53) ^e
Female Genital System	~	~	~	~	~	~	~
Cervix Uteri	~	~	~	~	~	~	~
Corpus and Uterus, NOS	~	~	~	~	~	~	~
Corpus Uteri	~	~	~	~	~	~	~
Uterus, NOS	~	~	~	~	~	~	~
Ovary	~	~	~	~	~	~	~
Vagina	~	~	~	~	~	~	~
Vulva	~	~	~	~	~	~	~
Other Female Genital Organs	~	~	~	~	~	~	~
Male Genital System	146.3	165.5	249.2	0.88	(0.88 - 0.89) ^e	0.59	(0.58 - 0.59) ^e
Prostate	141.1	157.9	246.7	0.89	(0.88 - 0.90) ^e	0.57	(0.57 - 0.58) ^e
Testis	3.6	6.5	1.3	0.55	(0.53 - 0.57) ^e	2.68	(2.48 - 2.90) ^e
Penis	1.4	0.8	1.0	1.71	(1.55 - 1.90) ^e	1.46	(1.26 - 1.69) ^e
Other Male Genital Organs	0.2	0.2	0.2	0.92	(0.70 - 1.21)	1.00	(0.70 - 1.41)
Urinary System	40.0	61.3	38.2	0.65	(0.64 - 0.66) ^e	1.05	(1.02 - 1.07) ^e
Urinary Bladder	22.2	41.8	18.5	0.53	(0.52 - 0.55) ^e	1.20	(1.16 - 1.24) ^e
Kidney and Renal Pelvis	16.9	18.1	18.9	0.93	(0.91 - 0.96) ^e	0.89	(0.86 - 0.93) ^e
Ureter	0.5	1.0	0.3	0.56	(0.47 - 0.67) ^e	1.74	(1.33 - 2.28) ^e
Other Urinary Organs	0.3	0.4	0.5	0.74	(0.59 - 0.93) ^e	0.69	(0.52 - 0.91) ^e
Eye and Orbit	0.6	1.1	0.3	0.58	(0.51 - 0.67) ^e	2.14	(1.73 - 2.66) ^e
Brain and Other Nervous System	6.2	8.7	4.8	0.71	(0.69 - 0.74) ^e	1.29	(1.22 - 1.37) ^e
Brain	5.8	8.2	4.4	0.71	(0.68 - 0.74) ^e	1.32	(1.25 - 1.41) ^e
Cranial Nerves Other Nervous System	0.4	0.5	0.4	0.79	(0.67 - 0.94) ^e	0.94	(0.75 - 1.18)
Endocrine System	3.9	5.2	3.1	0.75	(0.71 - 0.79) ^e	1.23	(1.14 - 1.32) ^e
Thyroid	3.3	4.4	2.3	0.75	(0.71 - 0.79) ^e	1.44	(1.33 - 1.56) ^e
Other Endocrine including Thymus	0.6	0.8	0.9	0.75	(0.66 - 0.86) ^e	0.67	(0.57 - 0.78) ^e
Lymphoma	22.8	26.8	19.6	0.85	(0.83 - 0.87) ^e	1.16	(1.12 - 1.20) ^e
Hodgkin Lymphoma	3.0	3.4	2.8	0.87	(0.83 - 0.93) ^e	1.08	(1.00 - 1.16) ^e
Hodgkin - Nodal	2.9	3.3	2.7	0.87	(0.82 - 0.92) ^e	1.08	(1.00 - 1.17) ^e
Hodgkin - Extranodal	0.1	0.1	0.1	0.96	(0.69 - 1.35)	0.93	(0.61 - 1.42)
Non-Hodgkin Lymphoma	19.8	23.4	16.9	0.85	(0.83 - 0.87) ^e	1.17	(1.13 - 1.21) ^e
NHL - Nodal	13.1	16.4	11.3	0.80	(0.78 - 0.83) ^e	1.17	(1.12 - 1.21) ^e
NHL - Extranodal	6.7	7.0	5.6	0.95	(0.91 - 1.00) ^e	1.19	(1.12 - 1.26) ^e
Myeloma	6.5	6.3	12.8	1.04	(0.99 - 1.09)	0.51	(0.48 - 0.54) ^e
Leukemia	12.2	16.6	12.1	0.74	(0.71 - 0.76) ^e	1.01	(0.97 - 1.05)
Lymphocytic Leukemia	5.3	8.0	5.2	0.66	(0.63 - 0.69) ^e	1.01	(0.95 - 1.08)

Table 7 (Web Supplement). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Acute Lymphocytic Leukemia	2.2	1.7	0.9	1.34	(1.26 - 1.42) ^e	2.40	(2.17 - 2.65) ^e
Chronic Lymphocytic Leukemia	2.6	5.6	3.9	0.47	(0.44 - 0.51) ^e	0.68	(0.62 - 0.74) ^e
Other Lymphocytic Leukemia	0.4	0.8	0.3	0.52	(0.44 - 0.63) ^e	1.14	(0.88 - 1.47)
Myeloid and Monocytic Leukemia	6.0	7.4	5.7	0.81	(0.78 - 0.85) ^e	1.05	(0.99 - 1.12)
Acute Myeloid Leukemia	3.8	4.9	3.6	0.78	(0.74 - 0.83) ^e	1.04	(0.97 - 1.13)
Acute Monocytic Leukemia	0.3	0.3	0.1	0.81	(0.63 - 1.03) ^e	1.90	(1.31 - 2.77) ^e
Chronic Myeloid Leukemia	1.8	2.0	1.8	0.89	(0.82 - 0.97) ^e	0.98	(0.88 - 1.10)
Other Myeloid/Monocytic Leukemia	0.2	0.2	0.2	0.91	(0.69 - 1.20)	1.28	(0.88 - 1.87)
Other Leukemia	0.9	1.2	1.1	0.75	(0.65 - 0.86) ^e	0.76	(0.64 - 0.90) ^e
Other Acute Leukemia	0.5	0.5	0.5	0.85	(0.70 - 1.02)	0.99	(0.77 - 1.27)
Aleukemic, Subleukemic and NOS	0.4	0.6	0.7	0.67	(0.54 - 0.81) ^e	0.61	(0.48 - 0.77) ^e
Mesothelioma	1.4	2.3	1.0	0.63	(0.56 - 0.69) ^e	1.42	(1.23 - 1.65) ^e
Kaposi Sarcoma	1.8	0.7	2.2	2.72	(2.51 - 2.96) ^e	0.82	(0.75 - 0.90) ^e
Miscellaneous	12.3	13.7	17.0	0.90	(0.87 - 0.93) ^e	0.72	(0.69 - 0.75) ^e

Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999-2003.

^a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) and confidence intervals (CI) are 95% for rate ratios (RR); *c.f.* = compared with.

^b 18 most common cancer in male and female based upon Hispanic ethnicity.

^c The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations.

^d NHIA derived Hispanic origin.

^e Rate ratio is statistically significant ($P < 0.05$).

~: not applicable.

Table 7 (Web Supplement) (contd). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Female							
All Sites	327.2	430.2	389.9	0.76	(0.76 - 0.76) ^e	0.84	(0.83 - 0.84) ^e
Oral Cavity and Pharynx	4.2	6.4	5.8	0.66	(0.63 - 0.69) ^e	0.72	(0.68 - 0.77) ^e
Lip	0.2	0.4	0.1	0.49	(0.39 - 0.62) ^e	2.82	(1.89 - 4.26) ^e
Tongue	1.1	1.7	1.1	0.67	(0.61 - 0.74) ^e	0.98	(0.87 - 1.10)
Salivary Gland	0.7	0.9	0.9	0.77	(0.69 - 0.86) ^e	0.83	(0.72 - 0.95) ^e
Floor of Mouth	0.3	0.5	0.4	0.54	(0.44 - 0.66) ^e	0.60	(0.47 - 0.76) ^e
Gum and Other Mouth	1.0	1.3	1.3	0.73	(0.66 - 0.81) ^e	0.78	(0.69 - 0.88) ^e
Nasopharynx	0.3	0.3	0.5	1.04	(0.86 - 1.25)	0.61	(0.50 - 0.75) ^e
Tonsil	0.3	0.6	0.6	0.47	(0.39 - 0.56) ^e	0.45	(0.37 - 0.55) ^e
Oropharynx	0.1	0.2	0.3	0.52	(0.37 - 0.70) ^e	0.37	(0.26 - 0.52) ^e
Hypopharynx	0.2	0.3	0.4	0.46	(0.35 - 0.59) ^e	0.35	(0.26 - 0.46) ^e
Other Oral Cavity and Pharynx	0.1	0.2	0.2	0.66	(0.49 - 0.89) ^e	0.55	(0.39 - 0.78) ^e
Digestive System	72.2	71.8	91.9	1.01	(0.99 - 1.02)	0.79	(0.77 - 0.80) ^e
Esophagus	1.5	2.0	3.6	0.77	(0.71 - 0.84) ^e	0.43	(0.39 - 0.47) ^e
Stomach	9.1	4.0	9.1	2.28	(2.20 - 2.36) ^e	1.01	(0.96 - 1.05)
Small Intestine	1.2	1.4	2.4	0.86	(0.78 - 0.94) ^e	0.51	(0.46 - 0.57) ^e
Colon and Rectum	37.3	46.5	54.3	0.80	(0.79 - 0.81) ^e	0.69	(0.67 - 0.70) ^e
Colon excluding Rectum	27.7	35.1	43.3	0.79	(0.77 - 0.80) ^e	0.64	(0.63 - 0.65) ^e
Cecum	6.0	8.4	10.2	0.72	(0.69 - 0.75) ^e	0.59	(0.56 - 0.62) ^e
Appendix	0.4	0.6	0.5	0.74	(0.63 - 0.85) ^e	0.83	(0.69 - 0.99) ^e
Ascending Colon	5.1	6.6	7.7	0.77	(0.74 - 0.81) ^e	0.67	(0.63 - 0.70) ^e
Hepatic Flexure	1.4	1.8	2.0	0.76	(0.70 - 0.83) ^e	0.70	(0.63 - 0.77) ^e
Transverse Colon	2.1	3.2	3.8	0.65	(0.61 - 0.70) ^e	0.55	(0.51 - 0.60) ^e
Splenic Flexure	0.9	1.1	1.7	0.87	(0.78 - 0.96) ^e	0.52	(0.46 - 0.59) ^e
Descending Colon	1.5	1.8	2.9	0.82	(0.76 - 0.89) ^e	0.50	(0.46 - 0.55) ^e
Sigmoid Colon	7.8	9.1	10.1	0.86	(0.83 - 0.89) ^e	0.77	(0.74 - 0.80) ^e
Large Intestine, NOS	2.4	2.6	4.3	0.93	(0.87 - 0.99) ^e	0.56	(0.52 - 0.61) ^e
Rectum and Rectosigmoid Junction	9.6	11.4	11.1	0.84	(0.82 - 0.87) ^e	0.87	(0.84 - 0.91) ^e
Rectosigmoid Junction	3.1	3.6	3.3	0.87	(0.83 - 0.92) ^e	0.94	(0.88 - 1.01) ^e
Rectum	6.5	7.8	7.8	0.83	(0.80 - 0.86) ^e	0.84	(0.80 - 0.88) ^e
Anus, Anal Canal and Anorectum	1.5	1.6	1.4	0.89	(0.82 - 0.96) ^e	1.08	(0.97 - 1.20)
Liver and Intrahepatic Bile Duct	5.8	2.5	3.7	2.37	(2.27 - 2.48) ^e	1.59	(1.50 - 1.69) ^e
Liver	5.0	1.9	3.2	2.57	(2.45 - 2.69) ^e	1.56	(1.46 - 1.66) ^e
Intrahepatic Bile Duct	0.9	0.5	0.5	1.64	(1.46 - 1.84) ^e	1.82	(1.55 - 2.14) ^e
Hepatocellular	3.7	1.2	2.2	3.08	(2.91 - 3.26) ^e	1.68	(1.56 - 1.81) ^e
Gallbladder	3.0	1.2	1.7	2.42	(2.28 - 2.57) ^e	1.78	(1.64 - 1.94) ^e
Other Biliary	1.9	1.2	1.2	1.56	(1.44 - 1.68) ^e	1.56	(1.40 - 1.73) ^e
Pancreas	9.4	9.6	13.4	0.98	(0.95 - 1.01)	0.70	(0.68 - 0.73) ^e
Retroperitoneum	0.4	0.4	0.5	1.07	(0.92 - 1.24)	0.88	(0.73 - 1.06)
Peritoneum, Omentum and Mesentery	0.6	1.0	0.4	0.64	(0.57 - 0.73) ^e	1.58	(1.32 - 1.90) ^e
Other Digestive Organs	0.4	0.3	0.4	1.37	(1.16 - 1.60) ^e	1.12	(0.91 - 1.38)
Respiratory System	28.2	61.1	54.1	0.46	(0.45 - 0.47) ^e	0.52	(0.51 - 0.53) ^e
Nose, Nasal Cavity and Middle Ear	0.5	0.5	0.4	0.89	(0.77 - 1.03)	1.10	(0.91 - 1.33)
Larynx	0.9	1.7	2.3	0.56	(0.51 - 0.62) ^e	0.41	(0.37 - 0.46) ^e

Table 7 (Web Supplement) (contd). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Lung and Bronchus	26.7	58.7	51.3	0.46	(0.45 - 0.46) ^e	0.52	(0.51 - 0.53) ^e
Pleura	0.0	0.0	0.0	0.68	(0.28 - 1.48)	0.86	(0.29 - 2.45)
Trachea, Mediastinum and Other							
Respiratory Organs	0.1	0.1	0.1	0.73	(0.54 - 0.99) ^e	0.74	(0.51 - 1.08)
Bones and Joints	0.8	0.8	0.7	1.01	(0.91 - 1.11)	1.27	(1.12 - 1.45) ^e
Soft Tissue including Heart	2.5	2.5	2.7	0.98	(0.92 - 1.04)	0.89	(0.83 - 0.96) ^e
Skin excluding Basal and Squamous	5.0	17.3	1.8	0.29	(0.27 - 0.30) ^e	2.76	(2.57 - 2.96) ^e
Melanoma of the Skin	4.1	16.2	0.9	0.26	(0.24 - 0.27) ^e	4.36	(3.97 - 4.80) ^e
Other Non-Epithelial Skin	0.8	1.1	0.8	0.72	(0.65 - 0.80) ^e	0.96	(0.84 - 1.10)
Breast	92.6	134.4	113.4	0.69	(0.68 - 0.70) ^e	0.82	(0.81 - 0.83) ^e
Female Genital System	47.9	51.3	46.7	0.93	(0.92 - 0.95) ^e	1.03	(1.01 - 1.04) ^e
Cervix Uteri	14.7	7.9	13.2	1.85	(1.80 - 1.89) ^e	1.11	(1.08 - 1.15) ^e
Corpus and Uterus, NOS	18.7	25.0	19.9	0.75	(0.73 - 0.77) ^e	0.94	(0.91 - 0.97) ^e
Corpus Uteri	17.8	24.3	18.5	0.73	(0.72 - 0.75) ^e	0.96	(0.94 - 0.99) ^e
Uterus, NOS	0.9	0.7	1.4	1.35	(1.21 - 1.50) ^e	0.64	(0.57 - 0.72) ^e
Ovary	11.4	14.6	10.2	0.78	(0.76 - 0.80) ^e	1.12	(1.08 - 1.16) ^e
Vagina	0.9	0.7	1.1	1.28	(1.15 - 1.43) ^e	0.75	(0.66 - 0.85) ^e
Vulva	1.7	2.5	1.7	0.70	(0.65 - 0.75) ^e	1.04	(0.94 - 1.14)
Other Female Genital Organs	0.6	0.6	0.7	0.86	(0.76 - 0.97) ^e	0.84	(0.72 - 0.98) ^e
Male Genital System	~	~	~	~	~	~	~
Prostate	~	~	~	~	~	~	~
Testis	~	~	~	~	~	~	~
Penis	~	~	~	~	~	~	~
Other Male Genital Organs	~	~	~	~	~	~	~
Urinary System	15.7	20.4	17.0	0.77	(0.75 - 0.79) ^e	0.92	(0.89 - 0.95) ^e
Urinary Bladder	5.9	10.6	6.9	0.55	(0.53 - 0.58) ^e	0.85	(0.81 - 0.90) ^e
Kidney and Renal Pelvis	9.4	9.2	9.6	1.02	(0.99 - 1.05)	0.98	(0.94 - 1.02)
Ureter	0.3	0.4	0.2	0.67	(0.55 - 0.81) ^e	1.59	(1.21 - 2.10) ^e
Other Urinary Organs	0.1	0.1	0.3	1.00	(0.74 - 1.33)	0.35	(0.26 - 0.48) ^e
Eye and Orbit	0.5	0.8	0.2	0.60	(0.53 - 0.69) ^e	2.55	(2.05 - 3.17) ^e
Brain and Other Nervous System	5.0	6.2	3.6	0.81	(0.78 - 0.84) ^e	1.41	(1.33 - 1.49) ^e
Brain	4.6	5.7	3.1	0.80	(0.76 - 0.83) ^e	1.47	(1.39 - 1.57) ^e
Cranial Nerves Other Nervous System	0.4	0.5	0.5	0.93	(0.81 - 1.06)	0.95	(0.80 - 1.13)
Endocrine System	11.8	12.9	8.1	0.92	(0.89 - 0.94) ^e	1.47	(1.41 - 1.52) ^e
Thyroid	11.2	12.3	7.3	0.92	(0.89 - 0.94) ^e	1.53	(1.48 - 1.59) ^e
Other Endocrine including Thymus	0.6	0.6	0.7	0.91	(0.81 - 1.03)	0.78	(0.67 - 0.91) ^e
Lymphoma	16.7	19.5	13.3	0.86	(0.84 - 0.88) ^e	1.26	(1.22 - 1.30) ^e
Hodgkin Lymphoma	2.0	2.8	2.0	0.72	(0.67 - 0.76) ^e	0.99	(0.91 - 1.07)
Hodgkin - Nodal	1.9	2.7	1.9	0.71	(0.67 - 0.76) ^e	0.98	(0.91 - 1.07)
Hodgkin - Extranodal	0.1	0.1	0.1	0.86	(0.62 - 1.17)	1.09	(0.72 - 1.65)
Non-Hodgkin Lymphoma	14.7	16.7	11.2	0.88	(0.86 - 0.90) ^e	1.31	(1.26 - 1.35) ^e
NHL - Nodal	9.7	11.6	7.3	0.84	(0.81 - 0.86) ^e	1.33	(1.27 - 1.38) ^e
NHL - Extranodal	5.0	5.1	3.9	0.98	(0.94 - 1.02)	1.27	(1.19 - 1.34) ^e
Myeloma	4.9	4.0	9.4	1.23	(1.17 - 1.29) ^e	0.52	(0.49 - 0.54) ^e
Leukemia	8.4	9.8	7.8	0.86	(0.83 - 0.88) ^e	1.07	(1.03 - 1.12) ^e
Lymphocytic Leukemia	3.4	4.4	2.9	0.79	(0.75 - 0.83) ^e	1.17	(1.10 - 1.25) ^e

Table 7 (Web Supplement) (contd). Age-adjusted Incidence Rates^a for Expanded Cancer Sites^b by Race/Ethnicity and Sex in the Selected Areas^c in the United States, 1999-2003.

Sex/Cancer Site	Hispanic ^d Rate	Non-Hispanic		Hispanic <i>c.f.</i>		Hispanic <i>c.f.</i>	
		White Rate	Black Rate	Non-Hispanic White RR	95% CI	Non-Hispanic Black RR	95% CI
Acute Lymphocytic Leukemia	1.8	1.2	0.7	1.48	(1.40 - 1.58) ^e	2.49	(2.25 - 2.75) ^e
Chronic Lymphocytic Leukemia	1.5	2.9	2.1	0.51	(0.46 - 0.55) ^e	0.71	(0.64 - 0.78) ^e
Other Lymphocytic Leukemia	0.1	0.3	0.2	0.58	(0.45 - 0.75) ^e	0.97	(0.70 - 1.35)
Myeloid and Monocytic Leukemia	4.3	4.7	4.0	0.91	(0.87 - 0.95) ^e	1.06	(1.00 - 1.13) ^e
Acute Myeloid Leukemia	2.9	3.2	2.7	0.90	(0.85 - 0.96) ^e	1.09	(1.01 - 1.17) ^e
Acute Monocytic Leukemia	0.2	0.2	0.1	0.89	(0.72 - 1.11)	1.52	(1.12 - 2.08) ^e
Chronic Myeloid Leukemia	1.1	1.2	1.1	0.97	(0.88 - 1.06)	1.03	(0.92 - 1.16)
Other Myeloid/Monocytic Leukemia	0.1	0.1	0.2	0.61	(0.43 - 0.84) ^e	0.56	(0.38 - 0.81) ^e
Other Leukemia	0.6	0.7	0.8	0.92	(0.81 - 1.04)	0.76	(0.66 - 0.89) ^e
Other Acute Leukemia	0.3	0.3	0.3	0.87	(0.72 - 1.04)	0.88	(0.70 - 1.11)
Aleukemic, Subleukemic and NOS	0.4	0.4	0.5	0.96	(0.81 - 1.14)	0.68	(0.56 - 0.84) ^e
Mesothelioma	0.4	0.5	0.2	0.86	(0.72 - 1.01)	1.68	(1.33 - 2.13) ^e
Kaposi Sarcoma	0.3	0.1	0.3	4.11	(3.32 - 5.05) ^e	1.15	(0.91 - 1.46)
Miscellaneous	10.2	10.5	12.9	0.97	(0.94 - 1.00)	0.79	(0.76 - 0.82) ^e

Source: SEER and NPCR areas reported by the North American Association of Central Cancer Registries as meeting high quality standards for 1999-2003.

^a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) and confidence intervals (CI) are 95% for rate ratios (RR); *c.f.* = compared with.

^b 18 most common cancer in male and female based upon Hispanic ethnicity.

^c The data from 38 cancer registries [Alabama, Alaska, California, Colorado, Connecticut, Delaware, District Of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, West Virginia, Wisconsin] were included covering 82% of U.S., 90% of the Hispanic, 81% of NHW and 79% of NHB populations..

^d NHIA derived Hispanic origin.

^e Rate ratio is statistically significant (P<0.05).

~: not applicable.